• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    RLX Technology Announces Unaudited Second Quarter 2023 Financial Results

    8/18/23 6:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email

    BEIJING, Aug. 18, 2023 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading branded e-vapor company in China, today announced its unaudited financial results for the second quarter ended June 30, 2023.

    Second Quarter 2023 Financial Highlights

    • Net revenues were RMB378.1 million (US$52.1 million) in the second quarter of 2023, compared with RMB2,233.9 million in the same period of 2022.
    • Gross margin was 26.1% in the second quarter of 2023, compared with 43.8% in the same period of 2022.
    • U.S. GAAP net income was RMB204.7 million (US$28.2 million) in the second quarter of 2023, compared with U.S. GAAP net income of RMB441.6 million in the same period of 2022.
    • Non-GAAP net income[1] was RMB86.2 million (US$11.9 million) in the second quarter of 2023, compared with RMB634.7 million in the same period of 2022.

    [1] Non-GAAP net income is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    "During the second quarter of 2023, we continued to firmly execute our core strategy amid the challenging market environment," said Ms. Ying (Kate) Wang, Co-founder, Chairperson of the Board of Directors, and CEO of RLX Technology. "Specifically, we remained dedicated to offering compliant, high-quality products while developing new products to meet users' evolving needs. Though the recent resurgence of illegal products has had a lingering impact on our sales, we believe the impact will be temporary rather than a major trend that could derail our recovery trajectory. As a trusted e-vapor brand for adult smokers, we remain confident that, supported by regulatory oversight, our premium products will continue to win users' trust and gradually supplant inferior and harmful illegal products. Moving forward, we will continue prioritizing product innovation, harm reduction, and quality control initiatives while further enhancing our product portfolio as we strive to create sustainable value for all stakeholders."

    Mr. Chao Lu, Chief Financial Officer of RLX Technology, commented, "In light of the external challenges, especially the disruptions from illegal products, we deepened our focus on efficiency and profitability improvement during the second quarter. Thanks to our supply chain optimizations and product design enhancements, our topline improved sequentially to RMB378.1 million, and our gross margin rebounded by 1.9 percentage points from the first quarter of 2023. We also strengthened cost control, which helped significantly narrow our non-GAAP operating loss. Notably, our operating cash flow turned positive for the first time since the new regulations were enacted. We believe our strong cash position will continue to support us in navigating the evolving markets, and we will pursue further gains in cost optimization and efficiency improvement to accelerate the pace of recovery."

    Second Quarter 2023 Financial Results

    Net revenues were RMB378.1 million (US$52.1 million) in the second quarter of 2023, compared with RMB2,233.9 million in the same period of 2022. The decrease was primarily due to the discontinuation of our older products and the negative impact of illegal products in the market after regulators' special action ended in April, which disrupted users' adoption of our new products that comply with national standards.

    Gross profit was RMB98.5 million (US$13.6 million) in the second quarter of 2023, compared with RMB977.9 million in the same period of 2022.

    Gross margin was 26.1% in the second quarter of 2023, compared with 43.8% in the same period of 2022. The decrease was primarily due to the imposition of a 36% excise tax which came into effect on November 1, 2022.

    Operating expenses were RMB47.2 million (US$6.5 million) in the second quarter of 2023, compared with RMB530.9 million in the same period of 2022. The decrease was primarily due to the change in share-based compensation expenses, which were positive RMB118.5 million (US$16.3 million) in the second quarter of 2023, compared with RMB193.2 million in the same period of 2022. The change in share-based compensation expenses consisted of (i) positive RMB15.3 million (US$2.1 million) recognized in selling expenses, (ii) positive RMB90.9 million (US$12.5 million) recognized in general and administrative expenses, and (iii) positive RMB12.2 million (US$1.7 million) recognized in research and development expenses. The change in share-based compensation expenses was primarily due to the changes in the fair value of the share incentive awards that the Company granted to its employees affected by the fluctuations of the Company's share price.

    Selling expenses were RMB45.2 million (US$6.2 million) in the second quarter of 2023, compared with RMB122.6 million in the same period of 2022, primarily due to the decrease in share-based compensation expenses.

    General and administrative expenses were positive RMB41.4 million (US$5.7 million) in the second quarter of 2023, compared with RMB290.7 million in the same period of 2022, mainly driven by the fluctuation of share-based compensation expenses.

    Research and development expenses were RMB43.3 million (US$6.0 million) in the second quarter of 2023, compared with RMB117.6 million in the same period of 2022, mainly driven by the decrease in share-based compensation expenses.

    Income from operations was RMB51.4 million (US$7.1 million) in the second quarter of 2023, compared with RMB446.9 million in the same period of 2022.

    Income tax expense was RMB51.5 million (US$7.1 million) in the second quarter of 2023, compared with RMB204.3 million in the same period of 2022.

    U.S. GAAP net income was RMB204.7 million (US$28.2 million) in the second quarter of 2023, compared with RMB441.6 million in the same period of 2022.

    Non-GAAP net income was RMB86.2 million (US$11.9 million) in the second quarter of 2023, compared with RMB634.7 million in the same period of 2022.

    U.S. GAAP basic and diluted net income per American depositary share ("ADS") were RMB0.154 (US$0.021) and RMB0.150 (US$0.021) in the second quarter of 2023, compared with U.S. GAAP basic and diluted net income per ADS of RMB0.348 and RMB0.347, respectively, in the same period of 2022.

    Non-GAAP basic and diluted net income per ADS[2] were RMB0.064 (US$0.009) and RMB0.062 (US$0.009), respectively, in the second quarter of 2023, compared with non-GAAP basic and diluted net income per ADS of RMB0.494 and RMB0.492, respectively, in the same period of 2022.

    [2] Non-GAAP basic and diluted net income per ADS is a non-GAAP financial measure. For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.

    Balance Sheet and Cash Flow

    As of June 30, 2023, the Company had cash and cash equivalents, restricted cash, short-term bank deposits, net, short-term investments, long-term bank deposits, net and long-term investment securities, net of RMB15,786.6 million (US$2,177.1 million), compared with RMB15,369.2 million as of March 31, 2023. For the second quarter ended June 30, 2023, net cash generated from operating activities was RMB41.3 million (US$5.7 million).

    Conference Call

    The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 18, 2023 (8:00 PM Beijing/Hong Kong Time on August 18, 2023).

    Dial-in details for the earnings conference call are as follows:

    United States (toll-free):

    +1-888-317-6003

    International:

    +1-412-317-6061

    Hong Kong, China (toll-free):

    +800-963-976

    Hong Kong, China:

    +852-5808-1995

    Mainland China:

    400-120-6115

    Participant Code:

    3325354

    Participants should dial in 10 minutes before the scheduled start time and ask to be connected to the call for "RLX Technology Inc." with the Participant Code as set forth above.

    Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.relxtech.com.

    A replay of the conference call will be accessible approximately two hours after the conclusion of the call until August 25, 2023, by dialing the following telephone numbers:

    United States:

    +1-877-344-7529

    International:

    +1-412-317-0088

    Replay Access Code:

    5550144

    About RLX Technology Inc.

    RLX Technology Inc. (NYSE:RLX) is a leading branded e-vapor company in China. The Company leverages its strong in-house technology, product development capabilities, and in-depth insights into adult smokers' needs to develop superior e-vapor products.

    For more information, please visit: http://ir.relxtech.com.

    Non-GAAP Financial Measures

    The Company uses non-GAAP net income and non-GAAP basic and diluted net income per ADS, each a non-GAAP financial measure, in evaluating its operating results and for financial and operational decision-making purposes. Non-GAAP net income represents net income excluding share-based compensation expenses. Non-GAAP basic and diluted net income per ADS is computed using non-GAAP net income attributable to RLX Technology Inc. and the same number of ADSs used in U.S. GAAP basic and diluted net income per ADS calculation.

    The Company presents these non-GAAP financial measures because they are used by the management to evaluate its operating performance and formulate business plans. The Company believes that they help identify underlying trends in its business that could otherwise be distorted by the effect of certain expenses that are included in net income. The Company also believes that the use of the non-GAAP measures facilitates investors' assessment of its operating performance, as they could provide useful information about its operating results, enhances the overall understanding of its past performance and future prospects and allows for greater visibility with respect to key metrics used by the management in its financial and operational decision making.

    The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools. They should not be considered in isolation or construed as an alternative to net income, basic and diluted net income per ADS or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review its historical non-GAAP financial measures to the most directly comparable U.S. GAAP measures. The non-GAAP financial measures here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. The Company encourages investors and others to review its financial information in its entirety and not rely on any single financial measure.

    For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliation of GAAP and non-GAAP Results" set forth at the end of this press release.

    Exchange Rate Information

    This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB7.2513 to US$1.00, the exchange rate on June 30, 2023, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

    Safe Harbor Statement

    This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and similar statements. Among other things, quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward- looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's growth strategies; its future business development, results of operations and financial condition; trends and competition in China's e-vapor market; changes in its revenues and certain cost or expense items; PRC governmental policies, laws and regulations relating to the Company's industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release and in the attachments is current as of the date of this press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

    For more information, please contact:

    In China:

    RLX Technology Inc.

    Head of Capital Markets

    Sam Tsang

    Email: [email protected] 

    Piacente Financial Communications

    Jenny Cai

    Tel: +86-10-6508-0677

    Email: [email protected] 

    In the United States:

    Piacente Financial Communications.

    Brandi Piacente

    Tel: +1-212-481-2050

    Email: [email protected] 

    RLX TECHNOLOGY INC.

    UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

    (All amounts in thousands)











    As of



    December 31,

    June 30,

    June 30,



    2022

    2023

    2023



    RMB

    RMB

    US$

    ASSETS







    Current assets:







    Cash and cash equivalents

    1,268,512

    1,761,694

    242,949

    Restricted cash

    20,574

    15,750

    2,172

    Short-term bank deposits, net

    7,084,879

    5,221,295

    720,049

    Receivables from online payment platforms

    3,000

    4,948

    682

    Short-term investments

    2,434,864

    2,210,005

    304,774

    Accounts and notes receivable, net

    51,381

    87,412

    12,055

    Inventories

    130,901

    90,178

    12,436

    Amounts due from related parties

    5,112

    38,352

    5,289

    Prepayments and other current assets, net

    198,932

    397,337

    54,795

    Total current assets

    11,198,155

    9,826,971

    1,355,201

    Non-current assets:







    Property, equipment and leasehold improvement, net

    87,871

    78,755

    10,861

    Intangible assets, net

    7,552

    6,977

    962

    Long-term investments, net

    8,000

    8,000

    1,103

    Deferred tax assets, net

    63,894

    63,894

    8,812

    Right-of-use assets, net

    75,008

    79,710

    10,993

    Long-term bank deposits, net

    1,515,428

    2,306,679

    318,106

    Long-term investment securities, net

    3,409,458

    4,271,197

    589,025

    Other non-current assets, net

    13,458

    8,029

    1,107

    Total non-current assets

    5,180,669

    6,823,241

    940,969

    Total assets

    16,378,824

    16,650,212

    2,296,170









    LIABILITIES AND SHAREHOLDERS' EQUITY







    Current liabilities:







    Accounts and notes payable

    269,346

    132,193

    18,230

    Contract liabilities

    75,226

    94,531

    13,036

    Salary and welfare benefits payable

    127,749

    94,050

    12,970

    Taxes payable

    109,676

    82,290

    11,348

    Amounts due to related parties

    423

    -

    -

    Accrued expenses and other current liabilities

    161,455

    120,058

    16,557

    Lease liabilities - current portion

    45,955

    49,286

    6,797

    Total current liabilities

    789,830

    572,408

    78,938











    Non-current liabilities:







    Deferred tax liabilities

    8,653

    8,653

    1,193

    Lease liabilities - non-current portion

    39,968

    38,878

    5,361

    Total non-current liabilities

    48,621

    47,531

    6,554

    Total liabilities

    838,451

    619,939

    85,492









    Shareholders' Equity:







    Total RLX Technology Inc. shareholders' equity

    15,569,060

    16,056,370

    2,214,279

    Noncontrolling interests

    (28,687)

    (26,097)

    (3,601)

    Total shareholders' equity

    15,540,373

    16,030,273

    2,210,678









    Total liabilities and shareholders' equity

    16,378,824

    16,650,212

    2,296,170











     

     

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

    COMPREHENSIVE INCOME/(LOSS)

    (All amounts in thousands, except for share and per share data)





















    For the three months ended



    For the six months ended



    June 30,

    March 31,

    June 30,

    June 30,



    June 30,

    June 30,

    June 30,



    2022

    2023

    2023

    2023



    2022

    2023

    2023



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



















    Net revenues

    2,233,893

    188,877

    378,123

    52,146



    3,948,343

    567,000

    78,193

    Cost of revenues

    (1,256,010)

    (78,693)

    (171,733)

    (23,683)



    (2,313,457)

    (250,426)

    (34,535)

    Excise tax on products

    -

    (64,458)

    (107,853)

    (14,874)



    -

    (172,311)

    (23,763)

    Gross profit

    977,883

    45,726

    98,537

    13,589



    1,634,886

    144,263

    19,895



















    Operating expenses:

















    Selling expenses

    (122,634)

    (85,761)

    (45,226)

    (6,237)



    (198,581)

    (130,987)

    (18,064)

    General and administrative expenses

    (290,745)

    (256,504)

    41,368

    5,705



    (224,350)

    (215,136)

    (29,669)

    Research and development expenses

    (117,567)

    (76,682)

    (43,317)

    (5,974)



    (141,574)

    (119,999)

    (16,549)

    Total operating expenses

    (530,946)

    (418,947)

    (47,175)

    (6,506)



    (564,505)

    (466,122)

    (64,282)



















    Income/(loss) from operations

    446,937

    (373,221)

    51,362

    7,083



    1,070,381

    (321,859)

    (44,387)



















    Other income:

















    Interest income, net

    42,724

    148,803

    162,888

    22,463



    69,875

    311,691

    42,984

    Investment income  

    40,631

    21,385

    20,588

    2,839



    72,870

    41,973

    5,788

    Others, net

    115,586

    129,157

    21,380

    2,948



    232,443

    150,537

    20,760

    Income/(loss) before income tax

    645,878

    (73,876)

    256,218

    35,333



    1,445,569

    182,342

    25,145

    Income tax (expense)/benefit  

    (204,316)

    17,571

    (51,502)

    (7,102)



    (316,952)

    (33,931)

    (4,679)

    Net income/(loss)

    441,562

    (56,305)

    204,716

    28,231



    1,128,617

    148,411

    20,466

    Less: net (loss)/income attributable to

         noncontrolling interests

    (19,499)

    661

    1,929

    266



    (37,725)

    2,590

    357

    Net income/(loss) attributable to RLX

         Technology Inc.

    461,061

    (56,966)

    202,787

    27,965



    1,166,342

    145,821

    20,109

    Other comprehensive loss:

















    Foreign currency translation adjustments

    580,438

    (148,096)

    563,078

    77,652



    534,614

    414,982

    57,229

    Unrealized income on long-term investment securities

    -

    2,873

    5,539

    764



    -

    8,412

    1,160

    Total other comprehensive income/(loss)

    580,438

    (145,223)

    568,617

    78,416



    534,614

    423,394

    58,389

    Total comprehensive income/(loss)

    1,022,000

    (201,528)

    773,333

    106,647



    1,663,231

    571,805

    78,855

    Less: total comprehensive (loss)/income

         attributable to noncontrolling interests

    (19,499)

    661

    1,929

    266



    (37,725)

    2,590

    357

    Total comprehensive income/(loss) attributable

         to RLX Technology Inc.

    1,041,499

    (202,189)

    771,404

    106,381



    1,700,956

    569,215

    78,498



















    Net income/(loss) per ordinary share/ADS 

















     Basic

    0.348

    (0.043)

    0.154

    0.021



    0.877

    0.111

    0.015

     Diluted

    0.347

    (0.043)

    0.150

    0.021



    0.867

    0.108

    0.015



















    Weighted average number of ordinary

         shares/ADSs

















    Basic

    1,323,877,777

    1,316,798,713

    1,318,628,588

    1,318,628,588



    1,329,964,500

    1,317,718,705

    1,317,718,705

    Diluted

    1,330,060,097

    1,316,798,713

    1,353,296,802

    1,353,296,802



    1,345,014,312

    1,348,021,483

    1,348,021,483

     

     

    RLX TECHNOLOGY INC.

    UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS

    (All amounts in thousands, except for share and per share data)













    For the three months ended



    For the six months ended



    June 30,

    March 31,

    June 30,

    June 30,



    June 30,

    June 30,

    June 30,



    2022

    2023

    2023

    2023



    2022

    2023

    2023



    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$

    Net income/(loss)

    441,562

    (56,305)

    204,716

    28,231



    1,128,617

    148,411

    20,466

    Add: share-based compensation expenses

















           Selling expenses

    17,896

    23,955

    (15,338)

    (2,115)



    (24,043)

    8,617

    1,188

           General and administrative expenses

    151,069

    201,343

    (90,923)

    (12,539)



    (79,018)

    110,420

    15,228

           Research and development expenses

    24,213

    14,654

    (12,229)

    (1,686)



    (28,998)

    2,425

    334

    Non-GAAP net income

    634,740

    183,647

    86,226

    11,891



    996,558

    269,873

    37,216



















    Net income/(loss) attributable to RLX Technology

         Inc.

    461,061

    (56,966)

    202,787

    27,965



    1,166,342

    145,821

    20,109

    Add: share-based compensation expenses

    193,178

    239,952

    (118,490)

    (16,340)



    (132,059)

    121,462

    16,750

    Non-GAAP net income attributable to RLX

         Technology Inc.

    654,239

    182,986

    84,297

    11,625



    1,034,283

    267,283

    36,859



















    Non-GAAP net income per ordinary share/ADS

















    - Basic

    0.494

    0.139

    0.064

    0.009



    0.778

    0.203

    0.028

    - Diluted

    0.492

    0.136

    0.062

    0.009



    0.769

    0.198

    0.027

    Weighted average number of ordinary

         shares/ADSs

















    - Basic

    1,323,877,777

    1,316,798,713

    1,318,628,588

    1,318,628,588



    1,329,964,500

    1,317,718,705

    1,317,718,705

    - Diluted

    1,330,060,097

    1,345,828,279

    1,353,296,802

    1,353,296,802



    1,345,014,312

    1,348,021,483

    1,348,021,483

     

     

    RLX TECHNOLOGY INC.



    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



    (All amounts in thousands)

























    For the three months ended



    For the six months ended





    June 30,

    March 31,

    June 30,

    June 30,



    June 30,

    June 30,

    June 30,





    2022

    2023

    2023

    2023



    2022

    2023

    2023





    RMB

    RMB

    RMB

    US$



    RMB

    RMB

    US$



    Net cash generated from/(used in) operating

         activities

    1,444,388

    (230,686)

    41,339

    5,701



    1,752,557

    (189,347)

    (26,112)



    Net cash (used in)/generated from investing

         activities

    (4,145,885)

    381,954

    431,683

    59,532



    (5,096,649)

    813,637

    112,206



    Net cash (used in)/generated from financing

         activities

    (145,189)

    4,346

    (199,080)

    (27,454)



    (306,801)

    (194,734)

    (26,855)



    Effect of foreign exchange rate changes on cash,

         cash equivalents and restricted cash

    171,597

    10,409

    48,393

    6,673



    151,041

    58,802

    8,109



    Net (decrease)/increase in cash and cash

         equivalents and restricted cash

    (2,675,089)

    166,023

    322,335

    44,452



    (3,499,852)

    488,358

    67,348



    Cash, cash equivalents and restricted cash at

         the beginning of the period

    4,384,704

    1,289,086

    1,455,109

    200,669



    5,209,467

    1,289,086

    177,773



    Cash, cash equivalents and restricted cash at

         the end of the period

    1,709,615

    1,455,109

    1,777,444

    245,121



    1,709,615

    1,777,444

    245,121



     

    Cision View original content:https://www.prnewswire.com/news-releases/rlx-technology-announces-unaudited-second-quarter-2023-financial-results-301904346.html

    SOURCE RLX Technology Inc.

    Get the next $RLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    SEC Filings

    View All

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    12/31/25 6:03:48 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    11/14/25 6:02:26 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by RLX Technology Inc.

    6-K - RLX Technology Inc. (0001828365) (Filer)

    8/22/25 7:09:03 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RLX Technology downgraded by Citigroup with a new price target

    Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

    3/17/25 7:42:34 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    UBS initiated coverage on RLX Technology with a new price target

    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RLX Technology Extends US$500 Million Share Repurchase Program

    SHENZHEN, China, Dec. 31, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that its board of directors has authorized the extension of its existing share repurchase program for an additional 24-month period through December 31, 2027. The existing share repurchase program was established in December 2021 and extended in December 2023. Under the current share repurchase program, the Company may repurchase up to US$500 million of its ordinary shares represented by ADSs until December 31, 2025. As of December 31, 2025, the Company had cumulatively repurchased approximately 170 million ordinary share

    12/31/25 3:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Financials

    Live finance-specific insights

    View All

    RLX Technology Announces Unaudited Third Quarter 2025 Financial Results

    SHENZHEN, China, Nov. 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Net revenues were RMB1,129.3 million (US$158.6 million) in the third quarter of 2025, compared with RMB756.3 million in the same period of 2024.Gross margin was 31.2% in the third quarter of 2025, compared with 27.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB187.8 million (US$26.4 million) in the third quarter of 2025, compared with RMB84.0 million in the same period of 2024.U

    11/14/25 4:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology to Report Third Quarter 2025 Financial Results on November 14, 2025

    - Earnings Call Scheduled for 7:00 a.m. ET on November 14, 2025 - SHENZHEN, China, Nov. 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025, before the U.S. markets open on Friday, November 14, 2025. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 14, 2025 (8:00 PM Beijing/Hong Kong Time on November 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-

    11/3/25 1:00:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Announces Unaudited Second Quarter 2025 Financial Results

    SHENZHEN, China, Aug. 22, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenues were RMB880.0 million (US$122.8 million) in the second quarter of 2025, compared with RMB627.2 million in the same period of 2024.Gross margin was 27.5% in the second quarter of 2025, compared with 25.2% in the same period of 2024.Non-GAAP income from operations[1] was RMB116.2 million (US$16.2 million) in the second quarter of 2025, compared with RMB46.9 million in the same period of 2024.U.S

    8/22/25 5:30:00 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/7/24 6:06:29 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/6/24 4:01:28 PM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

    SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

    2/14/23 6:01:42 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care